Xarelto rivaroxaban regulatory update

The U.K.'s NICE issued final guidance recommending the use of Xarelto rivaroxaban from Bayer for the drug's approved indication of treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism (PE) following an acute DVT. The recommendation is in line a May final appraisal determination (see BioCentury, June 4). DVT is the third indication for which NICE has recommended Xarelto. The committee previously recommended the oral Factor Xa inhibitor to prevent stroke and systemic embolism in patients with atrial fibrillation (AF); and to prevent venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery. ...